Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linezolid-rifampin versus standard of care for gram-positive prosthetic hip joint infection
2012-000781-38Phase 2Completed
- Sponsor
- CHRU Tours
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in periprosthetic joint infection (PJI) and Gram-positive bacterial infection comparing Linezolid + rifampin with Standard of care (2 arms). Primary endpoint: Cure rate at 12 months post-treatment. Started Jul 2012; status: completed.
02
Drugs
linezolidrifampicin
03
Conditions
periprosthetic joint infection (PJI)Gram-positive bacterial infection
Beyond the preview
Go deeper on 2012-000781-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000781-38.